Table 1.
Controls,* n = 279 | All patients, n = 225 | Male patients, n = 116 | Female patients, n = 109 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||||||
Symptoms, no. (%) | Symptoms, no. (%) | Symptoms, no. (%) | |||||||||||||
|
|
|
|||||||||||||
Genotype | No. (%) | OR (95% CI) | p value | No | Yes | OR (95% CI) | p value | No | Yes | OR (95% CI) | p value | No | Yes | OR (95% CI) | p value |
GG | 118 (42.2) | 1.0 | 55 (47.0) | 30 (27.8) | 1.0 | 30 (48.4) | 10 (18.5) | 1.0 | 25 (45.5) | 20 (37.0) | 1.0 | ||||
GT/TT | 161 (57.7) | 1.19 (0.83–1.70) | 0.33 | 62 (53.0) | 78 (72.2) | 2.40 (1.37–4.22) | 0.002† | 32 (51.6) | 44 (81.5) | 4.13 (1.77–9.65) | < 0.001‡ | 30 (54.5) | 34 (63.0) | 1.55 (0.71–2.41) | 0.27 |
CI = confidence interval; OR = odds ratio.
Odds ratios were calculated for controls compared with patients with obsessive–compulsive disorder considered as a whole. No information on subclinical obsessive symptoms for any symptom dimension was available for controls.
Corrected for sex and age.
Corrected for age.